Current Report Filing (8-k)
November 05 2019 - 05:27PM
Edgar (US Regulatory)
0001590560 false 00-0000000 0001590560
2019-11-04 2019-11-05 iso4217:USD xbrli:shares iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 5, 2019
uniQure N.V.
(Exact Name of Registrant as Specified in Charter)
The
Netherlands |
|
001-36294 |
|
N/A |
(State or Other
Jurisdiction of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
Paasheuvelweg 25a,
1105 BP
Amsterdam, The
Netherlands |
|
N/A |
(Address of Principal Executive
Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: +31-20-566-7394
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see
General Instruction A.2. below):
¨ Written
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class: |
|
Trading Symbol(s) |
|
Name of each exchange on which registered: |
Ordinary
Shares, par value €0.05 per share |
|
QURE |
|
The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the
Exchange Act. ¨
Item 7.01 Regulation FD Disclosure.
On November 5, 2019, uniQure N.V. (the “Company”) issued a press
release announcing the issuance by the U.S. Patent and Trademark
Office of a new patent providing for further protection of the
Company’s Padua and Padua-related variants of Factor IX in gene
therapy. A copy of the press release is furnished as Exhibit 99.1
to this Current Report on Form 8-K and is incorporated by reference
herein.
In accordance with General Instruction B.2 of Form 8-K, the
information set forth in this Item 7.01 and Exhibit 99.1 are
“furnished” and shall not be deemed to be “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities of that
section, nor shall such information be deemed incorporated by
reference into any filing under the Securities Act of 1933, as
amended, or the Exchange Act.
Item 9.01 Financial Statements and Exhibits
(d) Exhibit
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
|
UNIQURE
N.V. |
|
|
|
|
Date: November
5, 2019 |
By: |
/S/ MATTHEW KAPUSTA |
|
|
Matthew Kapusta |
|
|
Chief Executive Officer and Chief
Financial Officer |
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Dec 2020 to Jan 2021
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jan 2020 to Jan 2021